AI Article Synopsis
- There is a significant need to enhance treatment results for Acute Myeloid Leukemia (AML).
- Recent research has advanced our knowledge of the genetic factors and mutations involved in AML through studies in cell cultures and mouse models.
- Validated mutations have paved the way for new targeted therapies that may improve the effectiveness and safety of AML treatments.
Article Abstract
There is still a compelling need to improve therapeutic outcome in AML. However, during the past several years our understanding of the genetic basis of AML, and the nature of the mutations that contribute to the phenotype, have been elucidated in cell culture and murine models of leukemia. The validation of various mutant leukemogenic gene products has in turn led to the development of an expanding group of molecular targeted therapies that have potential to improve the therapeutic window for treatment of AML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00277-004-0850-2 | DOI Listing |
Publication Analysis
Top Keywords
targeted therapies
8
improve therapeutic
8
therapies myeloid
4
myeloid leukemias
4
leukemias compelling
4
compelling improve
4
therapeutic outcome
4
outcome aml
4
aml years
4
years understanding
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!